Nektar Therapeutics

Novartis Ag

Michael A Eldon

Shibani S Harite

Tamra L Barker

Thomas E Tarara

Jeffry G Weers

Mei-chang Kuo

David Lechuga-Ballesteros

Sarvajna Kumar Dwivedi

Andrew Clark

Danforth Miller

Hema Gursahani

C Simone Jude-Fishburn

Ute Hoch

Sarma Duddu

Keith Washco

Alison Hannah

Richard Malcolmson

Alan Kugler

Theresa D Sweeney

Srinivas Palakodaty

Trixie Tan

Rangachari Narashimhan

Yen Lin Chia

Christopher Frantz

Myong Gyong Lee

Yiqiong Yuan

Abraham C F Leung

The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.

Methods of treating CYP2D6 alternative metabolizers

Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo. Sustained Exposure to Active Metabolite with PEG-Irinotecan

Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.

Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor

Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.

Methods for treating humans having brain cancer

Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.

Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.

Insulin derivative formulations for pulmonary delivery

Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.

Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 &#x3bc;m to about 1.9 &#x3bc;m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 &#x3bc;m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.

Compositions comprising amphotericin B, methods, and systems

Growing community of inventors

Redwood City, CA, United States of America

Michael A Eldon